loading page

SARS-CoV-2 (COVID-19) Vaccine Response in Liver Transplant Recipients
  • +4
  • Sebastian Sterling,
  • Yasmina Tashkent,
  • Cheng Sheng Chai,
  • Griffith Perkins,
  • Nicholas Rieger,
  • P. Toby Coates,
  • Alan Wigg
Sebastian Sterling
The University of Adelaide Faculty of Health and Medical Sciences

Corresponding Author:[email protected]

Author Profile
Yasmina Tashkent
Flinders Medical Centre
Author Profile
Cheng Sheng Chai
The University of Adelaide Faculty of Health and Medical Sciences
Author Profile
Griffith Perkins
The University of Adelaide Faculty of Health and Medical Sciences
Author Profile
Nicholas Rieger
Calvary North Adelaide Hospital
Author Profile
P. Toby Coates
The University of Adelaide Faculty of Health and Medical Sciences
Author Profile
Alan Wigg
Flinders Medical Centre
Author Profile

Abstract

Organ transplant recipients are at increased risk of contracting severe Covid due to their chronic immunosuppression, having both a significant increase in morbidity and mortality. Attempts to mitigate the contraction of COVID-19, the expeditious role out of the vaccines was first offered to those in this vulnerable subclass. Quickly established was the need for further booster doses to promote the immunological response in the immunosuppressed. This paper is a uni-centred study, exploring the anti-receptor binding domain (RBD) and anti-Spike immunoglobulin levels in a small subset of liver transplant recipients in Adelaide, South Australia, pre- and post 3rd administration of the SARS-CoV-2 vaccine. Peripheral bloods samples taken were compared to a group of health controls. The data showed that a minimum of three doses of the vaccine were required in the liver transplant patients, in order to express both anti-RBD and anti-Spike IgG to levels that were statistically comparable to that of healthy individuals.
08 May 2024Submitted to Immunity, Inflammation and Disease
09 May 2024Submission Checks Completed
09 May 2024Assigned to Editor
28 Jul 2024Reviewer(s) Assigned